Summary
The disposition of oral paracetamol (1.0 g 3 times daily for 10 days) was studied in 6 patients with end-stage renal failure (creatinine clearance <5 ml×min−1) maintained on haemodialysis 2 or 3 times per week. Blood was sampled daily for 10 days. The time of sampling depended on whether the patients were dialysed in the morning or afternoon but was always within 5 h of the last dose of paracetamol. On dialysis days samples were taken at the start of the session.
The mean plasma concentration of paracetamol was 6.8mg× 1−1 after the first 24 h and subsequently varied little throughout the 10 days. Apparent steady-state plasma concentrations of 60.0 mg×1−1 and 54.5 mg×1−1 were reached for the glucuronide and sulphate conjugate of paracetamol respectively by the 2nd day of treatment with little variation throughout the remainder of the study. These steady-state concentrations of paracetamol glucuronide and sulphate were much lower than predicted. The steady-state plasma concentrations of the retained cysteine and mercapturate conjugates of paracetamol were low (5.7 and 3.7 mg×1−1, respectively) and there was no evidence of accumulation of these potentially toxic metabolites.
It is not clear why regular dosing with paracetamol in haemodialysis patients did not cause the accumulation of paracetamol glucuronide or sulphate as predicted. There may be enterohepatic elimination of retained paracetamol conjugates or depletion of substrates such as inorganic sulphate during chronic dosing.
Similar content being viewed by others
References
Clements JA, Critchley JAJH, Prescott LF (1984) The role of sulphate conjugation in the metabolism and disposition of oral and intravenous paracetamol in man. Br J Clin Pharmacol 18: 481–485
Freeman RM, Richards CJ (1979) Studies on sulphate in end-stage renal disease. Kidney Int 15: 167–175
Galinsky RE, Levy G (1981) Dose- and time-dependent elimination of acetaminophen elimination in rats: pharmacokinetic implications of cosubstrate depletion. J Pharmacol Exp Ther 219: 14–20
Hendrix-Treacy S, Wallace SM, Hindmarsh KW, Wyant GM, Danilkewich A (1986) The effect of acetaminophen administration on its disposition and body stores of sulphate. Eur J Clin Pharmacol 30: 273–278
Holmes JH, Millar HS, Hlad CJ (1960) Serum and urine sulphate changes in uremia. Trans Am Soc Art Int Org 6: 163–175
Lin JH, Levy G (1981) Sulphate depletion after acetaminophen administration and replenishment by infusion of sodium sulphate or N-acetylcysteine in rats. Biochem Pharmacol 30: 2723–2727
Lin JH, Levy G (1982) Effect of experimental renal failure on sulphate retention and acetaminophen pharmacokinetics in rats. J Pharmacol Exp Ther 221: 80–84
Martin U, Temple RM, Winney RJ, Prescott LF (1991) The disposition of paracetamol and the accumulation of its glucuronide and sulphate conjugates during multiple dosing in patients with chronic renal failure. Eur J Clin Pharmacol 41: 43–46
Matthews JNS, Altman DG, Campbell MJ, Royston P (1990) Analysis of serial measurements in medical research. Br Med J 300: 230–235
Øie S, Lowenthal DT, Briggs WA, Levy G (1975) Effect of hemodialysis on kinetics of acetaminophen elimination by anephric patients. Clin Pharmacol Ther 18: 680–686
Prescott LF (1983) Paracetamol overdose: pharmacological considerations and clinical management. Drugs 25: 290–314
Prescott LF, Speirs GC, Critchley JAJH, Temple RM, Winney RJ (1989) Paracetamol disposition and metabolic kinetics in patients with chronic renal failure. Eur J Clin Pharmacol 36: 291–297
Siegers C-P, Klaassen CD (1984) Biliary excretion of acetaminophen in ureter-ligated rats. Pharmacol 28: 177–180
Verbeeck RK, Branch RA, Wilkinson GR (1981) Drug metabolites in renal failure: pharmacokinetic and clinical implications. Clin Pharmacokinet 6: 329–345
Wagner JG (1975) Fundamentals of clinical pharmacokinetics. Drug Intelligence Publications, Illinois
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Martin, U., Temple, R.M., Winney, R.J. et al. The disposition of paracetamol and its conjugates during multiple dosing in patients with end-stage renal failure maintained on haemodialysis. Eur J Clin Pharmacol 45, 141–145 (1993). https://doi.org/10.1007/BF00315495
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315495